Department of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195;
Department of Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195; and.
J Immunol. 2014 Jun 1;192(11):5098-108. doi: 10.4049/jimmunol.1303073. Epub 2014 Apr 30.
Hepatic stellate cells (HSC) are a major source of the immunoregulatory metabolite all-trans retinoic acid (ATRA), which may contribute to the generation of tolerogenic dendritic cells (DCs) in the liver. The present study seeks to clarify the mechanism(s) through which ATRA promotes the development of tolerogenic DCs. Although bone marrow-derived ATRA-treated DCs (RA-DCs) and conventional DCs had comparable surface phenotype, RA-DCs had diminished stimulatory capacity and could directly inhibit the expansion of DC/OVA-stimulated OT-II T cells. Arginase-1 (Arg-1) was found promote suppression because 1) ATRA was a potent inducer of Arg-1 protein and activity, 2) the Arg-1 inhibitor N(w)-hydroxy nor-l-arginine partially reversed suppression, and 3) the suppressive function of RA-DCs was partially compromised using OT-II T cells from GCN2(-/-) mice, which are insensitive to Arg-1. Inducible NO synthase (iNOS), however, was found to be a more significant contributor to RA-DC function because 1) ATRA potentiated the expression of IFN-γ-induced iNOS, 2) suppressive function in RA-DCs was blocked by the iNOS inhibitor N(G)-monomethyl-l-arginine, monoacetate salt, and 3) RA-DCs derived from iNOS(-/-) mice exhibited near complete loss of tolerogenic function, despite sustained Arg-1 activity. The expression of iNOS and the suppressive function of RA-DCs were dependent on both IFN-γ and ATRA. Furthermore, the in vivo behavior of RA-DCs proved to be consistent with their in vitro behavior. Thus, we conclude that ATRA enhances both Arg-1 and iNOS expression in IFN-γ-treated DCs, resulting in a tolerogenic phenotype. These findings elucidate mechanisms through which ATRA may contribute to liver immune tolerance.
肝星状细胞 (HSC) 是免疫调节代谢产物全反式视黄酸 (ATRA) 的主要来源,它可能有助于肝脏中耐受原性树突状细胞 (DC) 的产生。本研究旨在阐明 ATRA 促进耐受原性 DC 发育的机制。尽管骨髓来源的 ATRA 处理的 DC(RA-DC)和常规 DC 具有相似的表面表型,但 RA-DC 的刺激能力降低,并且可以直接抑制 DC/OVA 刺激的 OT-II T 细胞的扩增。发现精氨酸酶-1 (Arg-1) 促进抑制作用,因为 1)ATRA 是 Arg-1 蛋白和活性的有效诱导剂,2)Arg-1 抑制剂 N(w)-羟基-nor-l-精氨酸部分逆转抑制作用,以及 3)RA-DC 的抑制功能部分受损使用来自 GCN2(-/-) 小鼠的 OT-II T 细胞,这些细胞对 Arg-1 不敏感。然而,诱导型一氧化氮合酶 (iNOS) 被发现是 RA-DC 功能的更重要贡献者,因为 1)ATRA 增强了 IFN-γ 诱导的 iNOS 的表达,2)iNOS 抑制剂 N(G)-单甲基-l-精氨酸,单乙酸盐阻断了 RA-DC 的抑制功能,以及 3)来自 iNOS(-/-) 小鼠的 RA-DC 表现出几乎完全丧失的耐受原性功能,尽管 Arg-1 活性持续存在。iNOS 的表达和 RA-DC 的抑制功能依赖于 IFN-γ 和 ATRA。此外,RA-DC 的体内行为与其体外行为一致。因此,我们得出结论,ATRA 增强了 IFN-γ 处理的 DC 中 Arg-1 和 iNOS 的表达,导致耐受原性表型。这些发现阐明了 ATRA 可能有助于肝脏免疫耐受的机制。